FACTORS THAT INFLUENCE SURVIVAL RATE IN EXTRAOCULAR RETINOBLASTOMA PATIENTS AT CIPTO MANGUNKUSUMO HOSPITAL : 2018
Article Sidebar
-
retinoblastoma, prognosis, survival
Abstract
Introduction: Optimal therapeutic approach for extraocular retinoblastoma has not been determined. The prognosis of extraocular retinoblastoma compared with intraocular retinoblastoma remains relatively poor. The aim of our study is to describe the factors that influence the survival rate of extraocular retinoblastoma.
Methods: A retrospective study. Patients diagnosed with extraocular retinoblastoma in Cipto Mangunkusumo Hospital, within 1 January to 31 December 2018 were reviewed for patient and tumor characteristic, ocular management, and patient survival.
Result: During the study period, a total of 80 patients were diagnosed with retinoblastoma in our center, 41.2% had an extra-ocular extension The mean age at diagnosis was 25.57 months, with 56.7% being males. Leukocoria is the initial sign most often noticed by parents. The median lag period was 12 months. Neoadjuvant chemotherapy was performed in 96.7% of cases, that carried out an average of 3-4 cycles before enucleation/exenteration. At the end of September 2019, there were 17 deaths in our study. Overall survival was 19.82 months with a mean age of 27.6 months, whereas extraocular death time ranged from 4 months to 55 months.
Conclusion: Death was more common in patients with age at first symptom less than 24 months, bilateral retinoblastoma, lag period more than 12 months, advanced stage (IVB) and delayed therapy after proptosis more than 3 months.
Full text article
References
Ali MJ, Honavar SG, Reddy VAP. Orbital retinoblastoma: Present status and future challenges – A review. Saudi Journal of Ophthalmology. 2011;25(2):159–67.
Yusran M. Angka kesintasan pasien retinoblastoma [Penelitian Deskriptif]. universitas indonesia; 2012.
Ravindranath Y. Childhood Leukemia and Cancer, An Issue of Pediatric Clinics, E-Book. Elsevier Health Sciences; 2014. 353 p.
AlAli A, Kletke S, Gallie B, Lam W-C. Retinoblastoma for Pediatric Ophthalmologists. Asia Pac J Ophthalmol (Phila). 2018;7(3):160–8.
Sitorus RS, Moll AC, Suhardjono S, Simangunsong LS, Riono P, Imhof S, et al. The effect of therapy refusal against medical advice in retinoblastoma patients in a setting where treatment delays are common. Ophthalmic Genet. 2009;30(1):31–6.
Erwenne CM, Franco EL. Age and lateness of referral as determinants of extra-ocular retinoblastoma. Ophthalmic Paediatr Genet. 1989;10(3):179–84.
Finger PT, Harbour JW, Karcioglu ZA. Risk Factors for Metastasis in Retinoblastoma. Surv Ophthalmol. 2002;47(1):1–16.
Chawla B, Hasan F, Azad R, Seth R, Upadhyay AD, Pathy S, et al. Clinical presentation and survival of retinoblastoma in Indian children. Br J Ophthalmol. 2016;100(2):172–8.
Pant G, Verma N, Kumar A, Pooniya V, Gupta SK. Outcome of extraocular retinoblastoma in a resource limited center from low middle income country. Pediatr Hematol Oncol. 2017;34(8):419–24.
Essuman V, Ntim-amponsah CT, Akafo S, Renner L. Presentation of retinoblastoma at a paediatric eye clinic in ghana. - PubMed - NCBI. 2019.
Chantada G, Fandiño A, Casak S, Manzitti J, Raslawski E, Schvartzman E. Treatment of overt extraocular retinoblastoma. - PubMed - NCBI. 2019.
Jenkinson H. Retinoblastoma: diagnosis and management—the UK perspective. Arch Dis Child. 2015;100(11):1070–5.
Menon BS, Reddy SC, Maziah WM, Ham A, Rosline H. Extraocular retinoblastoma. Med Pediatr Oncol. 2000;35(1):75–6.
Sethi S, Pushker N, Kashyap S, Sharma S, Mehta M, Bakhshi S, et al. Extraocular retinoblastoma in Indian children: clinical, imaging and histopathological features. Int J Ophthalmol. 2013;6(4):481–6.
Gao J, Zeng J, Guo B, He W, Chen J, Lu F, et al. Clinical presentation and treatment outcome of retinoblastoma in children of South Western China. Medicine (Baltimore). 2016;95(42):e5204.
Menon BS, Alagaratnam J, Juraida E, Mohamed M, Ibrahim H, Naing NN. Late presentation of retinoblastoma in Malaysia. Pediatr Blood Cancer. 2009;52(2):215–7.
Antoneli CBG, Ribeiro KB, Rodriguez-Galindo C, Soares FA, Arias VA, Novaes PERS, et al. The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol. 2007;29(10):700–4.
Shields CL, Shields JA. Recent Developments in the Management of Retinoblastoma. 2019.
Radhakrishnan V, Kashyap S, Pushker neelam, Sharma S, Pathy S, mohanti bidhu, et al. Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadju... - PubMed - NCBI. 2019.
Shields CL, Honavar SG, Meadows AT. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. - PubMed - NCBI. 2019.
Chantada GL, Guitter MR, Fandiño AC, Raslawski EC, de Davila MTG, Vaiani E, et al. Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatr Blood Cancer. 2009;52(2):218–22.
Leander C, Ligia F, Pena A, C Howard S, Galindo CR, A Willimas J, et al. Impact of an education program on late diagnosis of retinoblastoma in Honduras. - PubMed - NCBI. 2019.
Authors
Copyright (c) 2024 Dwie Aprina, Julie Dewi Barliana, Dian Estu Yulia, Rita Sita Sitorus
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.